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Introduction {#s1}
============

Bisphenol A (BPA) is a high-production-volume chemical that is used to produce polycarbonate plastics and resins used in some food can linings, medical equipment, thermal receipts, and other consumer products ([@c16]; [@c23]). Exposure is ubiquitous among people in industrialized countries and is predominantly from diet ([@c13]; [@c50]). There is some evidence that prenatal BPA exposure may increase the risk of neurobehavioral disorders in children ([@c12]; [@c16]). Some experimental studies in rodents suggest that prenatal BPA exposure is associated with behavior problems and that these effects may be sex-specific ([@c42]; [@c46]); however, in other studies, no effects of BPA on rodent neurobehavior were observed ([@c41]). Prenatal exposure to BPA may increase the risk of neurobehavioral disorders by affecting thyroid or gonadal hormones or neurotransmitter systems, which are both necessary for proper brain development ([@c15]; [@c33]; [@c45]). BPA may also affect the production or metabolism of gonadal hormones, which are an important determinant of sexually dimorphic brain development; thus, BPA may differentially affect neurodevelopment in males and females ([@c3]; [@c32]; [@c53]).

Several epidemiological studies have reported that maternal urinary BPA concentration during pregnancy is associated with adverse behavioral outcomes ([@c9]; [@c14]; [@c24]; [@c27]; [@c44]), whereas others have not ([@c36]). The presence and direction of specific associations between BPA exposure and child neurobehavior has been heterogeneous in these studies. This variation may arise from differences in study design features and from misclassification of BPA exposure that is a result of the high within-person variability of urinary BPA concentrations ([@c10]). In addition, some studies have reported that child sex modifies the association between BPA and neurobehavior, but the modest sample size of these studies may have limited their statistical power to identify sex-specific associations. Finally, studies in animals show that gestational BPA exposure may affect specific aspects of cognition, such as memory and learning ([@c28]; [@c51]), but few studies have examined the relationship between prenatal BPA exposure and children's cognitive abilities ([@c9]; [@c14]).

To precisely estimate the potential neurotoxic effects of BPA exposure, we examined the relationship between maternal urinary BPA concentrations measured during pregnancy and children's behavior and cognitive abilities at 3 y of age in a prospective cohort study from Canada with follow-up data on 812 children.

Methods {#s2}
=======

Study Participants {#s2.1}
------------------

We used data from the Maternal--Infant Research on Environmental Chemicals (MIREC) study, a prospective cohort that recruited 2,000 women in the first trimester of pregnancy from obstetric and prenatal clinics in ten cities (11 study sites) across Canada from 2008 to 2011 (see [@c1] for additional details about eligibility, recruitment, and follow-up). Briefly, eligibility criteria included having the ability to consent and communicate in English or French, being $\geq 18$ y of age, having plans to deliver at a local hospital, and agreeing to participate in the cord blood collection component of the MIREC study. We excluded women who were carrying a fetus with a known malformation or abnormality and those with a history of major chronic disease, threatened abortion, and illicit drug use. Of the 8,716 women we approached to participate in MIREC, 5,108 (58.6%) were eligible, 1,983 (38.8%) consented to participate, and 1,910 had singleton live births. We conducted follow-up on 896 (46.9%) singleton children born to these women when the children were $\sim 3$ y old.

This research was approved by ethics review boards from Health Canada and Sainte-Justine Centre hospitalier universitaire (CHU) and Quebec CHU research centers and by ethics committees at the participating hospitals. Potential participants were provided with information about the objectives and design of the study and were asked to sign the informed consent forms for both the prenatal and child follow-up portions of the study.

Prenatal BPA Exposure Assessment {#s2.2}
--------------------------------

We collected a single urine sample from women at an average of 12.1 wk gestation (range: 5.1--15 wk), aliquoted the sample, froze the aliquots at $- 20{^\circ}C$ within 2 h of collection, and shipped them on dry ice to the MIREC coordinating center in Montreal, where they were stored at $- 30{^\circ}C$. Urine samples were shipped in batches to the Centre de Toxicologie du Québec, Institut National de Santé Publique du Québec for analysis. The total ($\text{conjugated} + \text{free}$) concentration of BPA was quantified using previously described analytic chemistry methods ([@c2]). The limit of detection (LOD) for this method was $0.2\;{ng/ml}$ , and we assigned values below the LOD a value of $0.1\;{ng/ml}$.

We accounted for individual variation in urine dilution by measuring urine specific gravity (SG) with a refractometer and standardizing urinary BPA concentrations using a formula adapted from Duty et al. ([@c22]): $$P_{s} = P_{i}\left( \frac{SG_{m} - 1}{SG_{i} - 1} \right)$$ where $P_{s}$ is the SG-standardized BPA concentration, $P_{i}$ is the observed BPA concentration for the $i–{th}$ woman, $SG_{m}$ is the median SG (1.013), and $SG_{i}$ is the observed SG for the $i–{th}$ woman.

Child Follow-up and Neurobehavioral Assessments {#s2.3}
-----------------------------------------------

Among 1,910 singleton children, 896 (46.9%) from all 11 MIREC study sites participated in at least one component of our child follow-up at an average age of 3.4 y (range: 2.8--4.2 y). Among these children, almost all of them completed internet-based or paper-and-pencil assessments of neurobehavior and covariates ($n = 812$ with complete exposure and covariate data). Owing to limited resources, we conducted in-person assessments of neurobehavior on children from seven MIREC study sites ($n = 544$ with complete exposure and covariate data). This in-person visit typically occurred in the participant's home, where trained research personnel collected urine and blood from the child, administered questionnaires, measured child anthropometry, and administered several neurobehavioral instruments to the child. Variation in sample size arose from incomplete questionnaires (parents did not complete the surveys) or invalid administration of in-person tests (e.g., inadequate testing environment).

We chose the tests described below for two reasons. First, previous studies report that the traits they measure are associated with prenatal exposure to environmental chemicals, including BPA ([@c9]; [@c20]; [@c27]). Second, some of these tests assess omnibus features of child neurodevelopment (e.g., IQ), whereas other tests measure specific features of clinical disorders such as attention deficit hyperactivity disorder (ADHD) (e.g., externalizing) and autism spectrum disorder (ASD) (e.g., affect recognition) ([@c21]; [@c31]).

The questionnaire-based assessment included the administration of the Behavioral Assessment System for Children--2 (BASC-2) and two subscales from the Behavior Rating Inventory of Executive Function--Preschool (BRIEF-P) to caregivers using an internet-based platform or paper-and-pencil versions. The BASC-2 is a valid and reliable 134-item assessment of children's problem behaviors in community and home settings ([@c43]). It provides three composite scores that measure children's total \[Behavioral Symptom Index (BSI)\], externalizing, and internalizing behavior problems, as well as seven clinical subscales measuring children's hyperactivity, aggression, anxiety, depression, somatization, atypicality, withdrawal, and attention. We assessed emerging metacognitive abilities in children by parent report using 27 items from the working memory and plan/organize subscales of the BRIEF-P, an instrument originally designed to measure children's executive function ([@c26]). Women were not aware of their urinary BPA concentration when they completed questionnaires about their child's behavior.

During the in-person assessment, parents completed the Social Responsiveness $\text{Scale™}–2$ (SRS-2), and children were administered the Wechsler Preschool and Primary Scales of $\text{Intelligence™}–\text{III}$ (WPPSI-III) and the Affect Recognition test from the NEPSY® (A Developmental NEuroPSYchological Assessment). The SRS-2 is a valid and reliable 65-item assessment of reciprocal social behaviors including interpersonal behaviors, communication, and repetitive or stereotypic behaviors ([@c6]). The SRS-2 provides a summary scale of all these behaviors, two scales of behaviors related to the Diagnostic and Statistical Manual--V (DSM-V) diagnostic criteria for autism spectrum disorders, and five subscales measuring social awareness, social cognition, social communication, social motivation, and restricted interests and repetitive behaviors. During the in-home visit, we administered the WPPSI-III, a valid and reliable assessment of children's cognitive abilities ([@c52]). Children completed the Receptive Vocabulary, Information, Block Design, Object Assembly, and Picture Naming subtests of the WPPSI-III in their home. Finally, we administered the Affect Recognition test of the NEPSY® during the in-home visit. This test assesses a child's ability to recognize emotions from photographs of children's faces; lower scores indicate that the child has poor visual attention, visual discrimination, or facial recognition ([@c30]). Study staff always attempted to provide an ideal and standardized environment for administering the WPPSI-III and the NEPSY® in the home; this included ensuring that the test area was well-lit, quiet, and free from distractions and interruptions.

We used software provided by the test publishers and U.S. population-based normative referent data to calculate full-scale IQ (FSIQ), verbal IQ (VIQ), and performance IQ (PIQ) scores for the WPPSI-III. Higher WPPSI-III scores indicate better cognitive abilities. We used these same methods to calculate T-scores for the BASC-2, the SRS-2, and the BRIEF-P. For these three tests, higher T-scores indicate more of the behavior or poorer functioning. Finally, we calculated scale scores for the Affect Recognition test of the NEPSY®: higher scores indicate better recognition of emotions.

Covariates {#s2.4}
----------

We assessed numerous factors that might confound the association between prenatal urinary BPA concentration and child neurobehavior. Trained interviewers administered standardized interviews during the first and third trimesters to assess maternal age at delivery, maternal race, maternal education, marital status, maternal employment, household income, self-reported smoking during pregnancy, alcohol consumption, multivitamin use, and parity. At the time of the child assessment, mothers completed standardized questionnaires or assessments that measured the duration of breastfeeding, parenting stress (Parenting Relationship Questionnaire), depressive symptoms (Center for Epidemiological Studies--Depression Scale 10), and self-reported delinquent behavior during adulthood. We also administered the Home Observation for the Measurement of the Environment (HOME) Inventory, a semi-structured interview that measures the quality and quantity of the caregiving environment ([@c7]).

We identified confounders by using directed acyclic graphs (DAGs) to select variables that were associated with both urinary BPA concentration and at least one neurobehavioral outcome, but not those that were causal intermediates or colliders (see Figure S1). We used the same set of covariates for all analyses. We also considered adjusting for study site because urinary BPA concentrations and measurement of children's behavior or cognitive abilities might vary across the study sites.

Statistical Methods {#s2.5}
-------------------

We began our statistical analyses by describing the central tendency and distribution of maternal urinary BPA concentrations and children's BSI, FSIQ, and SRS total scores by covariates. We examined the shape of the relationship between $\log_{2} - \text{transformed}$ urinary BPA concentration and neurobehavioral scores using 3-knot restricted cubic polynomial splines. We used multivariable linear regression to estimate the covariate-adjusted association between $\log_{2} - \text{transformed}$ urinary BPA concentration and neurobehavioral scores. In addition, we examined quintiles of urinary BPA concentration in relationship to some neurobehavioral outcomes to characterize the dose--response relationship. We used product interaction terms between child sex and prenatal urinary BPA concentration to estimate sex-specific associations and to test the difference in these associations between boys and girls.

We examined the impact of adjusting for study site by comparing models that did not adjust for study site, that included study site as a covariate, or that used generalized estimating equations (GEEs) to account for study site. Ultimately, we did not adjust for study site because adjusting for this variable did not meaningfully change our results, and the models using GEEs produced imprecise results when we examined quintiles of BPA exposure because of small sample sizes at one study site. We examined the magnitude and precision of individual point estimates as well as the pattern of estimates across neurobehavioral tests rather than relying solely on statistical significance testing.

We conducted a series of sensitivity analyses to assess the robustness of our results to various confounder adjustments. First, we compared our results with and without adjustment for covariates that were measured at the child follow-up visit (maternal depression, parenting stress, breastfeeding duration, and delinquent behavior) because these covariates may not be associated with prenatal urinary BPA concentration. Second, we adjusted for maternal receipt of welfare support ($n = 18$) and child age. Third, among children who completed the in-person visit, we adjusted for daycare attendance and the HOME Inventory. To avoid potential selection biases, we made comparisons between models adjusted for our primary covariates and those adjusted for our primary covariates plus daycare attendance and the HOME Inventory among the subset of children who completed the in-person follow-up. We also examined whether our method of accounting for urine dilution influenced our results by comparing results of models that adjusted for creatinine as a covariate with those that used SG-standardized BPA concentrations. Finally, because urinary BPA and phthalate metabolite concentrations may be correlated because of shared exposure sources (e.g., diet), and prenatal phthalate exposure may be associated with adverse neurodevelopment, we adjusted for maternal urinary concentrations of mono-ethyl phthalate, mono-*n*-butyl phthalate, mono-benzyl phthalate, and the sum of three di-2-ethylhexyl phthalate metabolites ([@c25]; [@c37]).

Results {#s3}
=======

Compared with mothers whose children did not complete follow-up, mothers of children who completed follow-up at 3 y of age were more likely to be older, white, better educated, married or living with their partner, employed, nonsmokers during pregnancy, and to use folic-acid supplements during pregnancy (see Table S2). Baseline maternal covariates were not substantially different among women whose children completed the questionnaire-based follow-up vs. in-person follow-up. Median maternal urinary BPA concentrations were similar among women who did ($0.8\;{ng/ml}$; $25{{th}\,}\text{percentile}:\, 0.3$, $75{{th}\,}\text{percentile}:\, 1.6$) and did not ($0.9\;{ng/ml}$; 25th: 0.4, 75th: 1.8) complete follow-up.

Among mothers whose children completed follow-up, urinary BPA concentration during pregnancy ranged from $< \text{LOD}$ to $79.1\;{ng/ml}$, and 86% of women had detectable concentrations. Median urinary BPA concentration did not substantially vary with covariates ([Table 1](#t1){ref-type="table"}). Mean BSI, SRS, and FSIQ scores were 51 \[$\text{standard}\,\text{deviation}\,\left( \text{SD} \right) = 7$\], 45 ($\text{SD} = 6$), and 107 ($\text{SD} = 14$), respectively. FSIQ scores were higher than the expected mean of 100, whereas SRS scores were lower than the expected mean of 50. Mean BSI, SRS, and FSIQ scores differed with several covariates. On average, FSIQ scores were lower and BSI and SRS scores were higher among children whose mothers were less educated, had lower household income, had greater parenting stress, and had more depressive symptoms.

###### 

Central tendency and variation of maternal urinary BPA concentration during pregnancy and child BASC-2 BSI, SRS total, and WPPSI-III FSIQ scores at 3 y of age according to covariates: MIREC study.

Table 1 lists variables in the first column; the corresponding n values and median for BPA, BSI, SRS, and FSIQ are listed in the other columns.

  Variable                                      BPA   BSI              SRS   FSIQ                          
  --------------------------------------------- ----- ---------------- ----- -------- ----- -------- ----- ----------
  Overall                                       812   0.8 (0.5, 1.5)   808   51 (7)   537   45 (6)   541   107 (14)
  Maternal age, years                                                                                       
   18--25                                       26    1 (0.6, 2.2)     26    50 (4)   14    48 (7)   15    103 (12)
   $> 25–35$                                    493   0.8 (0.5, 1.5)   490   51 (7)   339   46 (6)   340   107 (14)
   $> 35$                                       293   0.8 (0.4, 1.3)   292   50 (7)   184   45 (6)   186   107 (14)
  Maternal Race                                                                                             
   White                                        702   0.8 (0.5, 1.5)   700   51 (7)   462   45 (6)   462   108 (13)
   Asian/Pacific Islander                       27    0.5 (0.3, 1.2)   27    51 (6)   15    46 (5)   16    109 (11)
   Other                                        49    0.8 (0.4, 1.4)   47    51 (8)   36    48 (6)   39    96 (14)
   Multiracial                                  34    0.7 (0.4, 1.5)   34    50 (6)   24    46 (6)   24    107 (15)
  Maternal education                                                                                        
   Graduate degree                              229   0.7 (0.4, 1.3)   229   50 (6)   145   44 (5)   146   110 (12)
   University degree                            325   0.9 (0.5, 1.5)   324   51 (7)   221   45 (7)   222   108 (14)
   Some college, trade school, or diploma       214   0.8 (0.5, 1.8)   211   51 (7)   147   46 (6)   148   103 (14)
   High school or less                          44    0.9 (0.4, 1.6)   44    51 (8)   24    47 (7)   25    99 (11)
  Marital status                                                                                            
   Married or living with partner               791   0.8 (0.5, 1.4)   788   50 (7)   520   45 (6)   524   107 (14)
   Not married or living alone                  21    1 (0.7, 2)       20    54 (9)   17    49 (7)   17    101 (15)
  Household Income (CAD)                                                                                    
   $> 100,000$                                  330   0.8 (0.5, 1.3)   329   50 (7)   215   44 (6)   217   109 (13)
   $80,000\,\text{to}\, 100,000$                270   0.8 (0.4, 1.4)   269   51 (7)   175   45 (6)   176   106 (14)
   $40,000\,\text{to} < 80,000$                 136   0.9 (0.6, 2.1)   134   51 (6)   92    47 (7)   93    103 (14)
   $< 40,000$                                   76    1 (0.5, 1.9)     76    52 (8)   55    48 (6)   55    104 (14)
  Employment                                                                                                
   No                                           93    0.9 (0.5, 1.7)   93    52 (8)   61    47 (9)   61    102 (17)
   Yes                                          719   0.8 (0.5, 1.4)   715   50 (7)   476   45 (6)   480   107 (13)
  Parity                                                                                                    
   0                                            357   0.9 (0.5, 1.6)   355   51 (7)   236   46 (6)   239   108 (14)
   1                                            332   0.7 (0.4, 1.4)   330   51 (7)   217   45 (6)   217   106 (14)
   $\geq 2$                                     123   0.8 (0.5, 1.2)   123   50 (6)   84    45 (7)   85    103 (12)
  Maternal smoking                                                                                          
   No                                           783   0.8 (0.5, 1.5)   779   51 (7)   521   45 (6)   525   107 (13)
   Yes                                          29    0.8 (0.6, 1.5)   29    51 (9)   16    49 (7)   16    98 (16)
  Prenatal alcohol use                                                                                      
   No                                           448   0.8 (0.5, 1.5)   445   51 (6)   306   45 (6)   309   106 (14)
   Yes                                          364   0.8 (0.5, 1.4)   363   50 (7)   231   45 (6)   232   108 (13)
  Prenatal folic acid supplement use                                                                        
   No                                           534   0.8 (0.5, 1.5)   531   51 (7)   362   45 (6)   367   106 (14)
   Yes                                          278   0.8 (0.4, 1.4)   277   50 (7)   175   45 (6)   174   108 (13)
  Duration of exclusive breastfeeding, months                                                               
   $\geq 6$                                     416   0.8 (0.5, 1.3)   415   51 (6)   266   45 (6)   268   108 (13)
   $< 6$                                        396   0.9 (0.5, 1.6)   393   51 (7)   271   46 (6)   273   105 (14)
  Parenting Stress                                                                                          
   Low                                          682   0.8 (0.5, 1.4)   681   49 (6)   448   44 (5)   450   108 (13)
   High                                         130   0.9 (0.4, 1.7)   127   56 (7)   89    52 (8)   91    102 (17)
  Maternal delinquency after high school                                                                    
   No delinquent behaviors                      662   0.8 (0.4, 1.4)   659   50 (6)   429   45 (6)   432   108 (14)
   Any delinquent behaviors                     150   1 (0.5, 1.7)     149   53 (8)   108   47 (7)   109   104 (14)
  Maternal CES-D Score                                                                                      
   $< 16$                                       785   0.8 (0.4, 1.4)   782   50 (7)   518   45 (6)   522   107 (14)
   $\geq 16$                                    27    1 (0.8, 1.8)     26    54 (7)   19    48 (5)   19    107 (12)
  Child sex                                                                                                 
   Male                                         399   0.8 (0.5, 1.5)   397   51 (7)   262   46 (7)   266   104 (15)
   Female                                       413   0.8 (0.4, 1.4)   411   50 (6)   275   44 (5)   275   109 (12)

Note: BPA, bisphenol A; BASC-2, Behavioral Assessment System for Children--2; BSI, behavior symptom index of the BASC-2; CES-D, Center for Epidemiologic Studies Depression Scale; FSIQ, full-scale IQ of the Wechsler Preschool and Primary Scales of Intelligence; MIREC, Maternal--Infant Research on Environmental Chemicals; SD, standard deviation; SRS, total T-Score from the Social Responsiveness $\text{Scale™}$; WPPSI-III, Wechsler Preschool and Primary Scales of $\text{Intelligence™}$, 3rd edition.

We observed linear associations between prenatal urinary BPA concentrations and children's behavior or cognitive ability scores (results not shown, all nonlinear term $p - \text{values} > 0.08$ from spline models). Among all children and after adjustment for covariates, we observed few notable associations between prenatal urinary BPA concentration during pregnancy and children's BASC-2, BRIEF-P, WPPSI-III, and NEPSY® scores ([Table 2](#t2){ref-type="table"}). However, child sex modified the associations between prenatal urinary BPA concentration during pregnancy and internalizing and somatization scores on the BASC-2, as well as working memory and plan/organize scores on the BRIEF-P (effect measure modification $p - \text{values} < 0.10$). In boys, each doubling in prenatal urinary BPA concentration was associated with more internalizing ($\beta = 0.5$; 95% CI: $- 0.1$, 1.1) and somatizing ($\beta = 0.6$; 95% CI: 0.0, 1.2) behaviors as well as with poorer BRIEF-P working memory ($\beta = 1.0$; 95% CI: 0.3, 1.7) and plan/organize ($\beta = 0.6$; 95% CI: $- 0.1$, 1.2) scores, whereas the associations were null or slightly inverse in among girls ([Table 2](#t2){ref-type="table"}).

###### 

Adjusted difference in behavioral and cognitive test score at 3 y of age with doubling in specific gravity standardized maternal urinary BPA concentrations during pregnancy: MIREC study.

Table 2 lists neurodevelopmental tests in the first column; the corresponding n values and beta values for all children, boys, and girls are listed in the other columns. The BPA x sex p-values are listed in the last column.

  Neurodevelopmental test      $n$    All children: $\beta$ (95% CI)   Boys: $\beta$ (95% CI)              Girls: $\beta$ (95% CI)             ${BPA} \times {Sex}$*p*-value
  ---------------------------- ----- -------------------------------- ------------------------ ----------------------------------------------- -------------------------------
  BASC-2 Summary Scales                                                                                                                         
   BSI                         808          0.1 ($- 0.1$, 0.4)           0.3 ($- 0.2$, 0.7)                  0.1 ($- 0.3$, 0.4)                0.5349
   Externalizing               808          0.0 ($- 0.4$, 0.3)           0.1 ($- 0.4$, 0.6)                $- 0.1$ ($- 0.5$, 0.4)              0.6268
   Internalizing               806          0.1 ($- 0.3$, 0.5)           0.5 ($- 0.1$, 1.1)                $- 0.2$ ($- 0.7$, 0.3)              0.0817
  BASC-2 Clinical Scales                                                                                                                        
   Hyperactivity               809          0.0 ($- 0.4$, 0.3)           0.1 ($- 0.5$, 0.6)                $- 0.1$ ($- 0.5$, 0.4)              0.7262
   Aggression                  808          0.0 ($- 0.3$, 0.4)           0.2 ($- 0.4$, 0.7)                  0.0 ($- 0.5$, 0.5)                0.6046
   Anxiety                     803          0.0 ($- 0.4$, 0.5)           0.0 ($- 0.7$, 0.8)                  0.0 ($- 0.6$, 0.6)                0.8772
   Depression                  808          0.3 ($- 0.1$, 0.7)           0.5 ($- 0.1$, 1.1)                  0.2 ($- 0.4$, 0.7)                0.3722
   Somatization                808          0.0 ($- 0.4$, 0.4)             0.6 (0.0, 1.2)                  $- 0.5$ ($- 1.0$, 0.0)              0.0063
   Atypicality                 809          0.1 ($- 0.3$, 0.4)           0.3 ($- 0.2$, 0.9)                $- 0.1$ ($- 0.6$, 0.3)              0.1871
   Withdrawal                  806          0.2 ($- 0.2$, 0.6)           0.0 ($- 0.6$, 0.6)                  0.4 ($- 0.2$, 0.9)                0.3666
   Attention                   812          0.0 ($- 0.1$, 0.2)           0.1 ($- 0.1$, 0.4)                  0.0 ($- 0.2$, 0.2)                0.5395
  BRIEF-P                                                                                                                                       
   Working Memory              810          0.1 ($- 0.3$, 0.6)             1.0 (0.3, 1.7)                  $- 0.5$ ($- 1.1$, 0.1)              0.0009
   Plan/Organize               812          0.0 ($- 0.5$, 0.4)           0.6 ($- 0.1$, 1.2)                $- 0.5$ ($- 1.0$, 0.1)              0.0258
  WPPSI-III Summary Scales                                                                                                                      
   FSIQ                        541          0.1 ($- 0.7$, 0.9)           0.7 ($- 0.4$, 1.9)                $- 0.3$ ($- 1.4$, 0.7)              0.1710
   VIQ                         538        $- 0.2$ ($- 1.0$, 0.5)         0.3 ($- 0.8$, 1.4)                $- 0.7$ ($- 1.7$, 0.3)              0.1660
   PIQ                         536          0.6 ($- 0.3$, 1.5)           1.1 ($- 0.3$, 2.4)                  0.2 ($- 1.0$, 1.4)                0.3433
  WPPSI-III Subtests                                                                                                                            
   Vocabulary                  544        $- 0.1$ ($- 0.2$, 0.1)         0.1 ($- 0.2$, 0.3)                $- 0.1$ ($- 0.4$, 0.1)              0.2259
   Block Design                541          0.1 ($- 0.1$, 0.3)           0.2 ($- 0.1$, 0.4)                  0.0 ($- 0.2$, 0.3)                0.4635
   Information                 531          0.0 ($- 0.2$, 0.1)           0.1 ($- 0.2$, 0.3)                $- 0.1$ ($- 0.3$, 0.1)              0.2088
   Object Design               541          0.1 ($- 0.1$, 0.3)           0.2 ($- 0.1$, 0.4)                  0.0 ($- 0.2$, 0.3)                0.3552
   Picture Completion          541          0.1 ($- 0.1$, 0.2)           0.2 ($- 0.1$, 0.4)                  0.0 ($- 0.2$, 0.2)                0.2863
  SRS-2                                                                                                                                         
   Total                       537            0.3 (0.0, 0.7)               0.5 (0.1, 1.0)                    0.2 ($- 0.2$, 0.6)                0.3090
   Awareness                   537          0.4 ($- 0.1$, 0.8)             0.6 (0.0, 1.3)                    0.2 ($- 0.4$, 0.7)                0.3008
   Cognition                   537            0.3 (0.0, 0.6)               0.5 (0.0, 1.0)                    0.2 ($- 0.3$, 0.6)                0.4361
   Communication               537            0.4 (0.0, 0.7)               0.5 (0.1, 1.0)                    0.2 ($- 0.2$, 0.6)                0.2777
   Motivation                  537          0.2 ($- 0.2$, 0.6)           0.3 ($- 0.3$, 1.0)                  0.0 ($- 0.5$, 0.6)                0.4628
   Restricted                  537            0.4 (0.0, 0.7)             0.4 ($- 0.2$, 0.9)                  0.3 ($- 0.2$, 0.8)                0.8306
   DSM Social                  537            0.3 (0.0, 0.6)               0.5 (0.1, 1.0)                    0.2 ($- 0.3$, 0.6)                0.2174
   DSM Restricted              537            0.4 (0.0, 0.7)             0.4 ($- 0.2$, 0.9)                  0.3 ($- 0.2$, 0.8)                0.8353
  NEPSY®: Affect Recognition   497        $- 0.1$ ($- 0.2$, 0.1)         0.1 ($- 0.2$, 0.3)     $- 0.1$ ($- 0.3$, 0.0) $- 0.1$ ($- 0.3$, 0.0)  0.1620

Note: Adjusted for maternal race, education, age, marital status, employment, smoking during pregnancy, alcohol use during pregnancy, folic acid supplement use during pregnancy, parity, months of exclusive breastfeeding, parental stress, and depressive symptoms. Positive coefficients for the BASC-2, BRIEF-P, and SRS indicate that BPA concentrations are associated with more behavior problems. Positive coefficients for the WPPSI-III and NESPY indicate that BPA is associated with better performance. BASC-2, Behavioral Assessment System for Children--2; BRIEF-P, Behavior Rating Inventory of Executive Function--Preschool; BPA, bisphenol A; BSI, behavior symptom index of the BASC-2; CI, confidence interval; DSM, Diagnostic and Statistical Manual of Mental Disorders; FSIQ, full-scale IQ; MIREC, Maternal--Infant Research on Environmental Chemicals; NEPSY®, A Developmental NEuroPSYchological Assessment; PIQ, performance IQ; SRS, Social Responsiveness $\text{Scale™}$, 2nd Edition; VIQ, verbal IQ; WPPSI, Wechsler Preschool and Primary Scales of $\text{Intelligence™}–\text{III}$.

For those BASC-2 scales exhibiting associations with prenatal urinary BPA concentration in boys, we further characterized the shape of the dose--response relationship using quintiles of prenatal urinary BPA concentration. Among boys, we observed a monotonic dose--response relationship between prenatal urinary BPA concentration and somatization score but not between prenatal urinary BPA concentration and internalizing, plan/organize, or working memory scores ([Figure 1](#f1){ref-type="fig"}; see also Table S3). For example, the mean somatization score among boys increased monotonically across all 5 quintiles of prenatal urinary BPA concentration, whereas internalizing scores were 2.4 points (95% CI: $- 0.1$, 4.9) higher among boys in the fourth quintile than those among boys in the first quintile, but only 0.9 points (95% CI: $- 1.7$, 3.5) higher among boys in the fifth quintile.

![Covariate adjusted mean child BASC-2 and BRIEF-P scores by maternal urinary BPA quintile: MIREC Study. Adjusted for maternal race, education, age, marital status, employment, smoking during pregnancy, alcohol use during pregnancy, folic acid supplement use, parity, months of exclusive breastfeeding, parental stress, and depressive symptoms. Maternal urinary BPA concentrations are specific-gravity standardized. Quintile ranges were $0.1\,\text{to} < 0.4\,\text{ng}/{mL}$, $0.4\,\text{to} < 0.7\,\text{ng}/{mL}$, $0.7\,\text{to} < 1.0\,\text{ng}/{mL}$, $1.0\,\text{to} < 1.7\,\text{ng}/{mL}$, and 1.7 to $79\;{ng/ml}$. Error bars represent the 95% confidence intervals. $n = 806$, 805, 810, and 812 for internalizing, somatization, plan/organize, and working memory, respectively. Note: The *y*-axis scale changes in each row. BASC-2, Behavioral Assessment System for Children--2; BPA, bisphenol A; BRIEF-P, Behavior Rating Inventory of Executive Function-Preschool; MIREC, Maternal--Infant Research on Environmental Chemicals.](EHP984_f1){#f1}

Each doubling in prenatal urinary BPA concentration during pregnancy was associated with higher scores on the SRS-2 among all children; the association was not modified by child sex (effect measure modification $p - \text{values}\, > 0.22$) ([Table 2](#t2){ref-type="table"}). Although SRS-2 scores tended to increase across prenatal urinary BPA quintiles, the increases were not consistently monotonic ([Figure 2](#f2){ref-type="fig"}, see also Table S4). For example, children in the second, third, fourth, and fifth quintiles of prenatal urinary BPA concentration had DSM-V social behavior scores that were 0.8 (95% CI: $- 0.5$, 2.2), 0 (95% CI: $- 1.0$, 1.3), 1.2 (95% CI: $- 0.1$, 2.6), and 1.5 (95% CI: 0.1, 2.9) points higher, respectively, than children in the first quintile. The associations between prenatal urinary BPA concentration and SRS scores related to social behaviors were stronger in boys than in girls, but the lowest $\text{sex} \times \text{BPA}$ *p*-value was 0.2174. Prenatal urinary BPA concentration was associated with poorer NEPSY®--II Affect Recognition score, but the 95% CI of the point estimate included the null value \[$\beta = - 0.1$ (95% CI: $- 0.2$, 0.1)\].

![Covariate adjusted mean child SRS-2 scores by maternal urinary BPA quintile: MIREC Study ($n = 537$). Adjusted for maternal race, education, age, marital status, employment, smoking during pregnancy, alcohol use during pregnancy, folic acid supplement use, parity, months of exclusive breastfeeding, parental stress, and depressive symptoms. Maternal urinary BPA concentrations are specific-gravity standardized. Quintile ranges were $0.1\,\text{to} < 0.4$, $0.4\,\text{to} < 0.7$, $0.7\,\text{to} < 1.0$, $1.0\,\text{to} < 1.7$, and 1.7 to $79\;{ng/ml}$. Error bars represent the 95% confidence intervals. Note: The y-axis scale changes in each row. BPA, bisphenol A; BRIEF-P, Behavior Rating Inventory of Executive Function-Preschool; MIREC, Maternal--Infant Research on Environmental Chemicals; RI/RB, restricted interests/repetitive behaviors.](EHP984_f2){#f2}

In sensitivity analyses, adjusting for covariates collected at 3 y of age, welfare receipt, child age, or HOME Inventory score generally did not appreciably change the results of our analyses for SRS scores or BASC-2 internalizing scores (see Figures S2 and S3). Although the association between BPA concentration and SRS scores was slightly attenuated after adjustment for welfare, the magnitude of these differences was $\leq 0.1$ points. For example, after adjustment for welfare, the association between BPA concentration and Social Cognition score was 0.3 (95% CI: $- 0.1$, 0.6), compared with 0.4 (95% CI: 0, 0.7) before adjustment. Associations between BPA concentration and internalizing or somatization score were unchanged when we accounted for urine dilution by adjusting for $\log_{10} - \text{transformed}$ creatinine concentration (see Figure S3); however, the associations between prenatal urinary BPA concentration and SRS scores were attenuated but more precise when adjusting for creatinine compared with using SG-standardized concentrations (see Figure S2). Adjustment for phthalate concentration did not substantially alter the associations of BPA with internalizing or SRS scores (see Figures S2 and S3).

Discussion {#s4}
==========

In this cohort, we observed that prenatal urinary BPA concentration was associated with poorer parent-reported reciprocal social behaviors as measured by the SRS-2 among both boys and girls. Furthermore, we observed some sex-specific associations where increasing prenatal urinary BPA concentration was positively correlated with more parent-reported somatization and internalizing behaviors and poorer parent-reported working memory and planning/organizing skills in boys, but not in girls. The associations between maternal urinary BPA concentration during pregnancy and other measures of children's cognitive abilities and behavior at 3 y of age were largely null.

Our study adds to a number of modestly sized studies ($n = 137 - 438$) examining prenatal BPA exposure and child neurobehavior ([@c9]; [@c14]; [@c24]; [@c27]; [@c36]; [@c44]). The sample size of the present study is a notable strength because it allowed us to more precisely estimate the presence and nature of sex-specific associations compared with prior studies. Consistent with the present results, four studies from three prospective cohorts reported that increasing prenatal urinary BPA concentration was associated with either internalizing or somatizing behaviors in children, with stronger associations in boys than in girls ([@c24]; [@c27]; [@c39]; [@c44]). In another cohort, prenatal BPA concentration was associated with more internalizing and externalizing behaviors in girls, but not in boys ([@c8], [@c9]). Another study found that prenatal BPA concentration was associated with an increased risk of ADHD-related behaviors at 4 y of age, with stronger associations in boys ([@c14]).

Previous studies have not reported associations between prenatal urinary BPA concentration and cognitive outcomes in children ([@c9]; [@c14]). The findings of Casas et al. ([@c14]) are consistent with our results of no association of prenatal BPA with child IQ or specific subtests of the WPPSI-III. Although we did observe an association of prenatal urinary BPA concentration with working memory and plan/organize scores in boys, a prior study using the BRIEF-P did not find an association (or modification by child sex) between prenatal urinary BPA concentration and working memory or plan/organize scores on the BRIEF-P ([@c9]).

Two prior studies reported that prenatal urinary BPA concentration was not associated with parent-reported reciprocal social behaviors and that these associations did not differ with respect to child sex ([@c11]; [@c36]). In contrast, we observed poorer reciprocal social behaviors among children born to women with higher prenatal urinary BPA concentrations. It should be noted that the associations between prenatal BPA concentration and SRS scores in this study were relatively modest, did not increase monotonically, and were typically largest in magnitude when comparing the fourth or fifth quintile with the first. There are several possible reasons for discrepant results across this and prior studies. First, urinary BPA concentration was lower among women in this study compared with most previous studies (median: 0.8 vs. $\sim 2\,\text{ng}/{mL}$) and in contrast to prior studies, we may have not had sufficient BPA exposure variation to detect associations. Second, although the different neurobehavioral assessments used across studies could be a source of variation, it will depend on the specific instrument and domain. For instance, externalizing and internalizing scores on the BASC-2 and those on the Child Behavior Checklist tend to be highly correlated (Pearson $R > 0.68$); in contrast, for some clinical domains, such as anxiety, the correlations are lower (Pearson $R < 0.35$) ([@c43]). Third, the timing and number of prenatal urinary BPA measures during pregnancy could influence study results if there are periods of heightened vulnerability to BPA exposure. One animal study observed that BPA exposure during organogenesis and breastfeeding caused morphine-induced hyperlocomotion, preference for drug-paired place, and up-regulation of dopamine receptor function, whereas exposure at other gestational time periods did not ([@c38]). However, there does not appear to be an obvious pattern between the observed epidemiological results and the timing of exposure assessment in this and prior studies. Finally, the timing of the neurobehavioral assessment could influence study results for traits that change as children age (e.g., anxiety) ([@c34]). Thus, associations between early-life toxicant exposure and child neurobehavior may not manifest until later in life; this phenomenon has been observed for other neurotoxicants such as polybrominated diphenyl ethers and methylmercury ([@c17]; [@c29]).

Given the episodic nature of BPA exposure and its short biological half-life ($< 6\; h$), there is substantial within-person variation of urinary BPA concentrations that makes accurate exposure assessment in epidemiological studies challenging ([@c10]; [@c48]). Thus, nondifferential BPA exposure misclassification may be responsible not only for attenuation of observed associations but also for heterogeneity in the literature. Our study measured BPA in only one urine sample from each woman, and this likely led to misclassification of the women's BPA exposure. A simulation study found that the high within-person variation of a urinary biomarker such as BPA leads to associations being biased toward the null and that it might be necessary to obtain $\geq 10$ repeated urine biomarkers from an individual or to analyze a pooled sample from each individual to limit bias in the effect estimate ([@c40]). Other approaches, including regression calibration techniques, could be used to account for nondifferential exposure measurement error in studies with only a single estimate of exposure for all participants and repeated measures on a subset.

We were unable to examine potential mechanisms of BPA action in this study but could do so in the future using stored biospecimens available in the MIREC Study ([@c1]). Prenatal BPA exposure may adversely affect a variety of biological processes during fetal development that are essential for proper neurodevelopment. In animal studies, BPA can affect the synthesis, action, transport, or metabolism of neurotransmitters, gonadal hormones, and thyroid hormones ([@c35]; [@c49]; [@c53]; [@c54]). BPA is a weak agonist of the nuclear estrogen receptors $\alpha$ and $\beta$ and may affect androgen/estrogen concentrations by inhibiting key enzymes involved in steroidogenesis ([@c35]; [@c53]). The ability of BPA to act on gonadal hormones may explain the sexually dimorphic associations we and others have observed because gonadal hormones play an important role in neurodevelopment ([@c19]). Other potential mechanisms of BPA action may include disruption of thyroid hormone homeostasis. In two epidemiological studies, prenatal urinary BPA concentration was associated with reduced neonatal thyroid stimulating hormone concentration, but the associations were observed in girls in one study and in boys in the other ([@c18]; [@c45]).

We observed relatively modest associations between prenatal urinary BPA concentration and specific aspects of child neurobehavior, particularly when considered from a clinical perspective. Despite this modest association, even subtle effects of BPA exposure could shift the distribution of continuous neurobehavioral traits to increase the risk of disorders such as autism spectrum disorders at the population level ([@c4]). Indeed, Bellinger has shown that despite the modest associations between some environmental toxicants and neurobehavioral traits at the clinical level, the ubiquitous nature of these exposures results in effects at the population level that are comparable to or exceed the population-level effects of clinical risk factors (e.g., preterm birth or iron deficiency) ([@c5]).

We comprehensively assessed numerous features of children's behaviors related to several neurodevelopmental disorders (e.g., anxiety, depression, ADHD, and ASD) and specific cognitive abilities. This is a notable strength because the majority of previous studies have only examined child behavior. However, our assessment of children's behaviors, working memory, and planning/organizing was limited to parental reports and could be enhanced in future studies by employing objective or teacher-reported measures of these domains.

A limitation of our study is that we were unable to adjust for other predictors of child behavior and cognition, specifically parental behavior and cognitive abilities. We note that adjustment for our primary set of covariates modestly attenuated the association between prenatal urinary BPA concentration and children's SRS scores, but additional adjustment for maternal receipt of welfare, caregiving environment, or daycare attendance did not appreciably change these associations. Thus, although residual confounding by other determinants of child neurobehavior is possible, these other factors would need to explain additional variation in our outcomes beyond those variables we adjusted for in our models and be associated with prenatal BPA exposure.

Finally, we only assessed BPA exposure during the first trimester of pregnancy, whereas exposure during other periods of fetal development, infancy, or childhood might affect neurodevelopment. Some previous studies have reported that childhood urinary BPA concentration is associated with child behaviors ([@c27]; [@c47]). Thus, identifying other periods of heightened vulnerability to BPA exposure in both the prenatal and postnatal periods remains an avenue of future research.

Conclusion {#s5}
==========

In the present study, maternal urinary BPA concentration during pregnancy was associated with some aspects of children's behaviors at 3 y of age: specifically, poorer reciprocal social behaviors among all children, more internalizing and somatization behaviors in boys, and poorer working memory and planning/organizing abilities in boys. Urinary BPA concentration during pregnancy was not associated with affect recognition, IQ, or externalizing behaviors, nor were these associations modified by child sex. Future investigations of early-life BPA exposure and child neurobehavior will need to reduce BPA exposure misclassification by conducting more extensive urine biomonitoring or by using measurement error correction methods.

Supplemental Material
=====================
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Click here for additional data file.
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